XNAS · Healthcare · Biotechnology
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.30 | -0.28 | +6.67% | $0 | ✅ Beat | +1.63% | -12.48% | — |
| 2026-03-27 | Q4 2025 | -0.34 | -0.20 | +41.18% | $0 | ✅ Beat | +0.00% | +29.35% | +6.30% |
| 2025-11-04 |
| Q3 2025 |
| -0.39 |
| -0.36 |
| +7.69% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.42 | -0.40 | +4.76% | $0 | mixed | +2.96% | -3.03% | +8.33% |
| 2025-03-11 | Q4 2024 | -0.28 | -0.46 | -64.29% | $0 | ❌ Miss | -2.38% | -7.94% | -48.10% |
| 2024-11-07 | Q3 2024 | -0.41 | -0.38 | +7.32% | $0 | ✅ Beat | +2.68% | -13.84% | -17.41% |
| 2024-05-03 | Q1 2024 | -0.35 | -0.39 | -11.43% | $742,000 | ❌ Miss | -1.48% | -16.80% | -34.27% |
| 2024-03-07 | Q4 2023 | -0.43 | -0.33 | +23.26% | $1.5M | ✅ Beat | — | — | — |
Showing last 8 quarters.